Azathioprine
- PDF / 169,283 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 109 Downloads / 164 Views
1 S
Various toxicities: 4 case reports In a retrospective study of 89 patients, treated with azathioprine between 2003 and 2014, 4 patients [ages and sexes not stated] were described, who developed skin rash, pancytopenia, infection or increased liver enzymes, during treatment with azathioprine for connective tissue disease associated interstitial lung disease (CTD-ILD) [routes and outcomes not stated; times to reactions onsets not clearly stated]. The patients, who had CTD-ILD, started receiving treatment with azathioprine at 50 mg/day, which was scheduled to be weekly increased by 50 mg/day up to the maintenance dose of 2 mg/kg/day. After 1 month, the dose was scheduled to be reduced by 10mg each month, until a maintenance dose of 10mg was reached. However, two of the 4 patients developed skin rash (n=1) or pancytopenia (n=1) within 3 months of azathioprine initiation, whereas the remaining two patients developed infection (n=1) or increased liver enzymes (n=1) after >3 months of azathioprine initiation. Azathioprine was discontinued. Boerner EB, et al. Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease. Respiration 99: 628-636, No. 8, Sep 2020. Available from: URL: http:// 803519545 doi.org/10.1159/000508540
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
